JAAOS - 2026-03-10 - Journal Article
Impact of GLP-1 Receptor Agonist Use on Total Knee Arthroplasty Outcomes in Metformin-Treated Diabetic Patients With and Without Comorbid Obesity: A Propensity-Matched Analysis.
Lee S, Sellig MT, Kim MT, Jayne C, Seo HH, Goh GS
Topics
Key Takeaway
GLP-1RA use in metformin-treated diabetic patients undergoing TKA reduced 90-day readmission in both obese (OR 0.776) and nonobese (OR 0.514) cohorts, with additional reduction in aseptic loosening at 2 years only in obese patients (OR 0.498).
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study queried the TriNetX Global Collaborative Network to determine whether perioperative GLP-1RA use improves TKA outcomes in metformin-treated T2DM patients stratified by obesity, using 1:1 propensity matching on age, sex, BMI, HbA1c, and comorbidities. In obese patients, GLP-1RA use reduced postoperative anemia (OR 0.714), AKI (OR 0.755), 90-day readmission (OR 0.776), ED visits (OR 0.836), and 2-year aseptic loosening (OR 0.498). In nonobese patients, benefits were limited to reduced 90-day readmission (OR 0.514) and ED visits (OR 0.649), with no significant differences in surgical complications or implant survivorship.
Key Limitation
The retrospective claims-based design cannot establish causality, and the aseptic loosening signal at 2 years is based on ICD-10 coding without radiographic or intraoperative confirmation, risking misclassification bias.
Original Abstract
INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been linked to improved outcomes following total knee arthroplasty (TKA). However, it remains unclear whether the observed benefits are attributable to weight loss, glycemic control, or first-line type 2 diabetes mellitus (T2DM) medications such as metformin. This study aimed to evaluate the impact of perioperative GLP-1RA use on TKA outcomes in T2DM patients stratified by obesity status.
METHODS
The TriNetX Global Collaborative Network was queried using relevant Current Procedural Terminology and ICD-10 codes for metformin-treated T2DM patients aged 18 years or older undergoing primary TKA. Patients were divided into two groups based on obesity status and further stratified based on GLP-1RA use within three months of surgery. The groups were propensity matched (1:1) based on age, sex, body mass index (BMI), HbA1c, and comorbidities. Surgical outcomes, medical complications, and resource utilization were assessed at 90 days and 1 year. Surgical outcomes and revision rates were also assessed at two years.
RESULTS
In obese patients (n = 8,170), GLP-1RA use was associated with notable reductions in postoperative anemia (odds ratio [OR] 0.714; P = 0.001), acute kidney injury (OR 0.755; P = 0.021), 90-day readmission (OR 0.776; P = 0.001), emergency department (ED) visits (OR 0.836; P = 0.008), and aseptic loosening at two years (OR 0.498; P = 0.037). These patients also demonstrated greater postoperative reductions in BMI and HbA1c. In nonobese patients (n = 1,328), GLP-1RA use was similarly associated with lower rates of 90-day readmission (OR 0.514; P = 0.004) and ED visits (OR 0.649; P = 0.024), although no notable differences in other outcomes were observed.
CONCLUSION
Among metformin-treated T2DM patients undergoing TKA, GLP-1RA use was associated with reduced resource utilization irrespective of obesity. However, additional reductions in medical complications and aseptic loosening were observed in the obese group, suggesting a potential synergistic effect between weight loss and glycemic control. These findings highlight the effectiveness of GLP-1RAs in optimizing high-risk candidates undergoing TKA.